Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma

Table 3 Prognostic factors for tumor response n (%)

Prognostic factors	Response (+)	Response (-)	P value
	CR, PR, SD	PD
Gender			0.716
Female	8 (73)	3 (27)
Male	43 (77)	13 (23)
Age (yr)			1.000
< 70	23 (77)	7 (23)
≥ 70	28 (76)	9 (24)
AFP (ng/mL)			0.123
< 400	25 (69)	11 (31)
≥ 400	23 (88)	3 (12)
BCLC			1.000
Advanced	46 (75)	15 (25)
Terminal	5 (83)	1 (17)
Child-Pugh			0.363
< 7	36 (80)	9 (20)
≥ 7	15 (68)	7 (32)
Diameter (mm)			0.401
< 30	29 (81)	7 (19)
≥ 30	22 (71)	9 (29)
Dose (Gy)			0.119
< 30	33 (70)	14 (30)
≥ 30	18 (90)	2 (10)
Dose/fraction (Gy)			0.137
< 8	22 (88)	3 (12)
≥ 8	29 (69)	13 (31)
Lesion			0.274
Intrahepatic	10 (91)	1 (9)
Extrahepatic	41 (73)	15 (27)
Fiducial			0.126
(-)	34 (71)	14 (29)
(+)	17 (89)	2 (11)
Sorafenib			0.460
(-)	43 (78)	12 (22)
(+)	8 (67)	4 (33)

Fisher's exact test was used to evaluate prognostic factors for tumor response. Complete response (CR), Partial response (PR) and stable disease (SD) were categorized into response (+), progressive disease (PD) was categorized into response (-).